CAR T-Cell trial for rare lymphoma halted after just one patient
Disease control
Terminated
This study tested a CAR T-cell therapy called axicabtagene ciloleucel in patients with a rare type of lymphoma (PMBCL) that had come back or not responded to initial treatment. The goal was to see if it could shrink tumors and improve outcomes. However, the trial was terminated e…
Phase: PHASE2 • Sponsor: Universität Münster • Aim: Disease control
Last updated Jun 26, 2026 14:13 UTC